Hemostasis	O
and	O
mechanism	O
of	O
action	O
of	O
selective	O
antimetastatic	O
drugs	O
in	O
mice	O
bearing	O
Lewis	B-Cancer
lung	I-Cancer
carcinoma	I-Cancer
.	O

The	O
selective	O
antimetastatic	O
agents	O
p	O
-	O
(	O
3	O
,	O
3	O
-	O
dimethyl	O
-	O
1	O
-	O
triazeno	O
)	O
benzoic	O
acid	O
potassium	O
salt	O
(	O
DM	O
-	O
COOK	O
)	O
,	O
5	O
-	O
(	O
3	O
,	O
3	O
-	O
dimethyl	O
-	O
1	O
-	O
triazeno	O
)	O
imidazole	O
-	O
4	O
-	O
carboxamide	O
(	O
DTIC	O
)	O
and	O
(	O
+	O
/	O
-	O
)	O
1	O
,	O
2	O
-	O
di	O
(	O
3	O
,	O
5	O
-	O
dioxopiperazin	O
-	O
1	O
-	O
yl	O
)	O
propane	O
(	O
ICRF	O
-	O
159	O
)	O
have	O
been	O
shown	O
to	O
markedly	O
depress	O
the	O
formation	O
of	O
spontaneous	O
hematogenous	O
metastases	B-Cancer
in	O
mice	O
bearing	O
s	O
.	O
c	O
.	O

Lewis	B-Cancer
lung	I-Cancer
carcinoma	I-Cancer
,	O
with	O
a	O
mechanism	O
unrelated	O
to	O
cytotoxicity	O
for	O
tumor	B-Cell
cells	I-Cell
.	O

The	O
effects	O
on	O
hemostasis	O
of	O
DM	O
-	O
COOK	O
,	O
DTIC	O
and	O
ICRF	O
-	O
159	O
have	O
thus	O
been	O
examined	O
in	O
comparison	O
with	O
those	O
of	O
a	O
purely	O
cytotoxic	O
agent	O
,	O
cyclophosphamide	O
,	O
in	O
mice	O
bearing	O
i	O
.	O
m	O
.	O

Lewis	B-Cancer
lung	I-Cancer
carcinoma	I-Cancer
.	O

The	O
parameters	O
considered	O
are	O
the	O
number	O
of	O
platelets	B-Cell
and	O
their	O
aggregability	O
,	O
prothrombin	O
and	O
partial	O
thromboplastin	O
times	O
,	O
plasma	B-Organism_substance
fibrinogen	O
concentration	O
and	O
tumor	B-Cell
cell	I-Cell
procoagulant	O
activity	O
.	O

Slight	O
variations	O
are	O
caused	O
by	O
drug	O
treatment	O
in	O
tumor	B-Cancer
-	O
bearing	O
mice	O
as	O
compared	O
with	O
untreated	O
tumor	B-Cancer
-	O
bearing	O
controls	O
;	O
the	O
pattern	O
of	O
effects	O
of	O
the	O
selective	O
antimetastatic	O
agents	O
does	O
not	O
differ	O
from	O
that	O
of	O
the	O
reference	O
cytotoxic	O
compound	O
used	O
,	O
cyclophosphamide	O
.	O

These	O
data	O
thus	O
indicate	O
that	O
the	O
effects	O
on	O
hemostasis	O
of	O
the	O
drugs	O
examined	O
can	O
contribute	O
only	O
marginally	O
to	O
their	O
antimetastatic	O
action	O
,	O
since	O
more	O
pronounced	O
effects	O
on	O
hemostasis	O
have	O
been	O
shown	O
to	O
be	O
required	O
to	O
significantly	O
affect	O
metastasis	O
formation	O
.	O

